Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Plasma pharmacokinetics and bioavailability of 1-(2-chloroethyl)-3-sarcosinamide-1-nitrosourea after intravenous and oral administration to mice and dogs.

Supko JG, Garcia-Carbonero R, Puchalski TA, Malspeis L.

Cancer Chemother Pharmacol. 2001 Sep;48(3):202-8.

PMID:
11592341
2.

Characterization of a novel degradation product of 2,2'-dithiobis[N-isoleucylbenzamide], an inhibitor of HIV nucleocapsid protein zinc fingers.

Phillips LR, Malspeis L, Tubbs EK, Supko JG.

J Pharm Biomed Anal. 2000 Aug 15;23(2-3):395-402.

PMID:
10933532
3.

Analysis of brefeldin A and the prodrug breflate in plasma by gas chromatography with mass selective detection.

Phillips LR, Wolfe TL, Malspeis L, Supko JG.

J Pharm Biomed Anal. 1998 Apr;16(8):1301-9.

PMID:
9777604
4.

2-Chloroethyl-3-sarcosinamide-1-nitrosourea, a novel chloroethylnitrosourea analogue with enhanced antitumor activity against human glioma xenografts.

Marcantonio D, Panasci LC, Hollingshead MG, Alley MC, Camalier RF, Sausville EA, Dykes DJ, Carter CA, Malspeis L.

Cancer Res. 1997 Sep 15;57(18):3895-8.

5.

Efficacy, pharmacokinetics, and in vivo antiviral activity of UC781, a highly potent, orally bioavailable nonnucleoside reverse transcriptase inhibitor of HIV type 1.

Buckheit RW Jr, Hollingshead M, Stinson S, Fliakas-Boltz V, Pallansch LA, Roberson J, Decker W, Elder C, Borgel S, Bonomi C, Shores R, Siford T, Malspeis L, Bader JP.

AIDS Res Hum Retroviruses. 1997 Jun 10;13(9):789-96.

PMID:
9171223
6.

Antiproliferative activity in vitro and in vivo of the spicamycin analogue KRN5500 with altered glycoprotein expression in vitro.

Burger AM, Kaur G, Hollingshead M, Fischer RT, Nagashima K, Malspeis L, Duncan KL, Sausville EA.

Clin Cancer Res. 1997 Mar;3(3):455-63.

7.

Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells.

Drees M, Dengler WA, Roth T, Labonte H, Mayo J, Malspeis L, Grever M, Sausville EA, Fiebig HH.

Clin Cancer Res. 1997 Feb;3(2):273-9.

8.
9.

Antiproliferative effect in vitro and antitumor activity in vivo of brefeldin A.

Sausville EA, Duncan KL, Senderowicz A, Plowman J, Randazzo PA, Kahn R, Malspeis L, Grever MR.

Cancer J Sci Am. 1996 Jan-Feb;2(1):52-8.

PMID:
9166499
10.

Inhibitors of HIV nucleocapsid protein zinc fingers as candidates for the treatment of AIDS.

Rice WG, Supko JG, Malspeis L, Buckheit RW Jr, Clanton D, Bu M, Graham L, Schaeffer CA, Turpin JA, Domagala J, Gogliotti R, Bader JP, Halliday SM, Coren L, Sowder RC 2nd, Arthur LO, Henderson LE.

Science. 1995 Nov 17;270(5239):1194-7.

PMID:
7502043
11.

In vivo drug screening applications of HIV-infected cells cultivated within hollow fibers in two physiologic compartments of mice.

Hollingshead M, Roberson J, Decker W, Buckheit R Jr, Elder C, Malspeis L, Mayo J, Grever M.

Antiviral Res. 1995 Nov;28(3):265-79.

PMID:
8629818
12.

Plasma pharmacokinetics of genistein in mice.

Supko J, Malspeis L.

Int J Oncol. 1995 Oct;7(4):847-54.

PMID:
21552913
13.

Tyrphostin AG17, [(3,5-Di-tert-butyl-4-hydroxybenzylidene)- malononitrile], inhibits cell growth by disrupting mitochondria.

Burger AM, Kaur G, Alley MC, Supko JG, Malspeis L, Grever MR, Sausville EA.

Cancer Res. 1995 Jul 1;55(13):2794-9. Erratum in: Cancer Res 1995 Aug 15;55(16):3684.

14.
15.

Jasplakinolide's inhibition of the growth of prostate carcinoma cells in vitro with disruption of the actin cytoskeleton.

Senderowicz AM, Kaur G, Sainz E, Laing C, Inman WD, Rodríguez J, Crews P, Malspeis L, Grever MR, Sausville EA, et al.

J Natl Cancer Inst. 1995 Jan 4;87(1):46-51.

PMID:
7666463
17.

Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent.

Supko JG, Hickman RL, Grever MR, Malspeis L.

Cancer Chemother Pharmacol. 1995;36(4):305-15.

PMID:
7628050
18.

In vivo cultivation of tumor cells in hollow fibers.

Hollingshead MG, Alley MC, Camalier RF, Abbott BJ, Mayo JG, Malspeis L, Grever MR.

Life Sci. 1995;57(2):131-41.

PMID:
7603295
19.

Growth and chemotherapeutic response of cells in a hollow-fiber in vitro solid tumor model.

Casciari JJ, Hollingshead MG, Alley MC, Mayo JG, Malspeis L, Miyauchi S, Grever MR, Weinstein JN.

J Natl Cancer Inst. 1994 Dec 21;86(24):1846-52.

PMID:
7990159
20.

Dose-dependent pharmacokinetics of rapamycin-28-N,N-dimethylglycinate in the mouse.

Supko JG, Malspeis L.

Cancer Chemother Pharmacol. 1994;33(4):325-30.

PMID:
8281627
21.
22.
23.

Analysis of brefeldin A in plasma by gas chromatography with electron capture detection.

Phillips LR, Supko JG, Malspeis L.

Anal Biochem. 1993 May 15;211(1):16-22.

PMID:
8323029
24.

The discovery and development of new antileukemic drugs.

Grever M, Malspeis L.

Hematol Oncol Clin North Am. 1993 Feb;7(1):233-54. Review.

PMID:
8449860
25.
26.

L-histidinol: preclinical therapeutic studies in combination with antitumor agents and pharmacokinetic studies in mice.

Zaharko D, Plowman J, Waud W, Dykes D, Malspeis L.

Cancer Res. 1992 Jul 1;52(13):3604-9.

28.

Characterization of the urinary metabolites of merbarone in cancer patients.

Supko JG, Malspeis L.

Drug Metab Dispos. 1991 Jan-Feb;19(1):263-73.

PMID:
1673412
29.

Immunological effects of flavone acetic acid.

Triozzi PL, Rinehart JJ, Malspeis L, Young DC, Grever MR.

Cancer Res. 1990 Oct 15;50(20):6483-5.

30.

A comprehensive phase I and II clinical investigation of fludarabine phosphate.

Grever M, Leiby J, Kraut E, Metz E, Neidhart J, Balcerzak S, Malspeis L.

Semin Oncol. 1990 Oct;17(5 Suppl 8):39-48.

PMID:
1699282
31.
32.

Limited sampling models for amonafide (NSC 308847) pharmacokinetics.

Ratain MJ, Staubus AE, Schilsky RL, Malspeis L.

Cancer Res. 1988 Jul 15;48(14):4127-30.

33.

Phase I clinical investigation of fludarabine phosphate by a loading-dose and continuous-infusion schedule.

Leiby JM, Grever MR, Staubus AE, Neidhart JA, Malspeis L.

J Natl Cancer Inst. 1988 May 18;80(6):447-9.

PMID:
2452888
34.
35.

Distribution of [2-14C]merbarone in mice by autoradiography of whole-body cryosections.

Kemmenoe BH, Malspeis L.

Cancer Res. 1987 Feb 15;47(4):1135-42.

36.

Merbarone: an antitumor agent entering clinical trials.

Glover A, Chun HG, Kleinman LM, Cooney DA, Plowman J, Grieshaber CK, Malspeis L, Leyland-Jones B.

Invest New Drugs. 1987;5(2):137-43. Review.

PMID:
3308762
37.

Phase I/II trial of human recombinant beta-interferon serine in patients with renal cell carcinoma.

Rinehart J, Malspeis L, Young D, Neidhart J.

Cancer Res. 1986 Oct;46(10):5364-7.

38.

Phase I/II trial of human recombinant interferon gamma in renal cell carcinoma.

Rinehart JJ, Malspeis L, Young D, Neidhart JA.

J Biol Response Mod. 1986 Aug;5(4):300-8.

PMID:
3090208
39.

Inhibition of uridine kinase and the salvage of uridine by modified pyrimidine nucleosides.

Moyer JD, Karle JM, Malinowski N, Marquez VE, Salam MA, Malspeis L, Cysyk RL.

Mol Pharmacol. 1985 Nov;28(5):454-60.

PMID:
2997596
40.

High-performance liquid chromatographic determination of pyrrolizine isopropyl carbamate.

Malspeis L, Abdel-Hay MH, Wahbi AA.

Analyst. 1985 Oct;110(10):1263-4. No abstract available.

PMID:
4083499
41.

Gas chromatographic determination of pyrazoloimidazole.

Malspeis L, Abdel-Hay MH, Wahbi AM.

J Chromatogr. 1985 Sep 13;343(1):190-5. No abstract available.

PMID:
4066854
42.

Phase I trial of teroxirone.

Neidhart JA, Derocher D, Grever MR, Kraut EH, Malspeis L.

Cancer Treat Rep. 1984 Sep;68(9):1115-9.

PMID:
6478450
43.

An enzymatic kinetic method for the determination of 2'-deoxycoformycin in biological fluids.

Staubus AE, Weinrib AB, Malspeis L.

Biochem Pharmacol. 1984 May 15;33(10):1633-7.

PMID:
6610419
44.

Metabolism of 4'-(9-acridinylamino)methanesulfon-m-anisidide by rat liver microsomes.

Shoemaker DD, Cysyk RL, Gormley PE, DeSouza JJ, Malspeis L.

Cancer Res. 1984 May;44(5):1939-45.

45.

The disposition and metabolism of tiazofurin in rodents, rabbits, and dogs.

Arnold ST, Jayaram HN, Harper GR, Litterst CL, Malspeis L, DeSouza JJ, Staubus AE, Ahluwalia GS, Wilson YA, Cooney DA.

Drug Metab Dispos. 1984 Mar-Apr;12(2):165-73.

PMID:
6144481
46.

Tiazofurin: a new antitumor agent.

O'Dwyer PJ, Shoemaker DD, Jayaram HN, Johns DG, Cooney DA, Marsoni S, Malspeis L, Plowman J, Davignon JP, Davis RD.

Invest New Drugs. 1984;2(1):79-84. Review.

PMID:
6381381
47.

Pharmacokinetics of 5,6-dihydro-5-azacytidine (NSC-264880) in the foxhound.

Malspeis L, Cheng H, Staubus AE.

Invest New Drugs. 1983;1(1):47-58.

PMID:
6206020
48.

Evidence for the nonenzymatic and irreversible binding of cytembena to rat liver microsomes in vitro.

Mayo JR, DeSouza JJ, Malspeis L, Feller DR.

Biochem Pharmacol. 1982 Oct 15;31(20):3201-5.

PMID:
6897357
49.

Concomitant adsorption and stability of some anthracycline antibiotics.

Tomlinson E, Malspeis L.

J Pharm Sci. 1982 Oct;71(10):1121-5.

PMID:
6958860
50.

Identification of the principal biliary metabolite of 4'-(9-acridinylamino)methanesulfon-m-anisidide in rats.

Shoemaker DD, Cysyk RL, Padmanabhan S, Bhat HB, Malspeis L.

Drug Metab Dispos. 1982 Jan-Feb;10(1):35-9.

PMID:
6124380

Supplemental Content

Loading ...
Support Center